ATE391915T1 - Verwendung des proteins grf-1 zur auswahl von molekülen - Google Patents
Verwendung des proteins grf-1 zur auswahl von molekülenInfo
- Publication number
- ATE391915T1 ATE391915T1 AT01963064T AT01963064T ATE391915T1 AT E391915 T1 ATE391915 T1 AT E391915T1 AT 01963064 T AT01963064 T AT 01963064T AT 01963064 T AT01963064 T AT 01963064T AT E391915 T1 ATE391915 T1 AT E391915T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- grf
- disease
- nervous system
- central nervous
- Prior art date
Links
- 101000703463 Homo sapiens Rho GTPase-activating protein 35 Proteins 0.000 title 1
- 102100030676 Rho GTPase-activating protein 35 Human genes 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 102000012990 ras-GRF1 Human genes 0.000 abstract 2
- 108010065206 ras-GRF1 Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 229940039781 leptin Drugs 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000016273 neuron death Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Conductive Materials (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0010539A FR2812945B1 (fr) | 2000-08-10 | 2000-08-10 | Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE391915T1 true ATE391915T1 (de) | 2008-04-15 |
Family
ID=8853473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01963064T ATE391915T1 (de) | 2000-08-10 | 2001-08-07 | Verwendung des proteins grf-1 zur auswahl von molekülen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050100972A1 (de) |
| EP (1) | EP1314040B1 (de) |
| JP (1) | JP4868692B2 (de) |
| AT (1) | ATE391915T1 (de) |
| AU (2) | AU2001284112B2 (de) |
| CA (1) | CA2418655C (de) |
| DE (1) | DE60133563T2 (de) |
| DK (1) | DK1314040T3 (de) |
| ES (1) | ES2304393T3 (de) |
| FR (1) | FR2812945B1 (de) |
| WO (1) | WO2002012901A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050208595A1 (en) * | 2004-03-19 | 2005-09-22 | Brown Arthur M | High throughput assay systems and methods for identifying agents that alter expression of cellular proteins |
| WO2012016963A1 (en) | 2010-08-02 | 2012-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Peptides for the treatment of brain diseases |
| US10528897B2 (en) * | 2011-04-28 | 2020-01-07 | Intuit Inc. | Graph databases for storing multidimensional models of software offerings |
| CN108614119A (zh) * | 2018-04-23 | 2018-10-02 | 南京医科大学第二附属医院 | 一种尿液exosome的蛋白标记物的检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5426029A (en) * | 1986-03-31 | 1995-06-20 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using leukocyte surface antigens |
| FR2690162B1 (fr) * | 1992-04-21 | 1995-08-04 | Rhone Poulenc Rorer Sa | Peptides ayant une activite de facteur d'echange du gdp, sequences d'acides nucleiques codant pour ces peptides, preparation et utilisation. |
| US5518911A (en) * | 1995-01-06 | 1996-05-21 | Onyx Pharmaceuticals, Inc. | Human PAK65 |
| ES2221942T3 (es) * | 1996-05-24 | 2005-01-16 | Aventis Pharma Deutschland Gmbh | Reactivo y metodo para inhibir la expresion de n-ras. |
| US5700821A (en) * | 1996-07-30 | 1997-12-23 | University Of Pittsburgh | Phosphatase inhibitors and methods of use thereof |
| US6238881B1 (en) * | 1996-11-06 | 2001-05-29 | Onyx Pharmaceuticals, Inc. | Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase |
| US6340575B1 (en) * | 1997-06-17 | 2002-01-22 | Onyx Pharmaceuticals, Inc. | Methods and compositions for treating abnormal cell growth related to unwanted guanine nucleotide exchange factor activity |
| GB9722320D0 (en) * | 1997-10-22 | 1997-12-17 | Janssen Pharmaceutica Nv | Human cell cycle checkpoint proteins |
| IT1306190B1 (it) * | 1999-01-04 | 2001-05-30 | Dipartimento Di Biotecnologie | Mutanti di proteine e plasmidi idonei per la loro sintesi. |
| CA2259830A1 (en) * | 1999-01-20 | 2000-07-20 | Hsc Research And Development Limited Partnership | Ras activator nucleic acid molecules, proteins and methods of use |
| US6589773B1 (en) * | 2000-02-17 | 2003-07-08 | Morphochem, Inc. | Methods and compositions for a modified yeast strain with increased permeability and uses thereof |
-
2000
- 2000-08-10 FR FR0010539A patent/FR2812945B1/fr not_active Expired - Fee Related
-
2001
- 2001-08-07 EP EP01963064A patent/EP1314040B1/de not_active Expired - Lifetime
- 2001-08-07 DE DE60133563T patent/DE60133563T2/de not_active Expired - Lifetime
- 2001-08-07 AU AU2001284112A patent/AU2001284112B2/en not_active Ceased
- 2001-08-07 AU AU8411201A patent/AU8411201A/xx active Pending
- 2001-08-07 CA CA2418655A patent/CA2418655C/fr not_active Expired - Fee Related
- 2001-08-07 AT AT01963064T patent/ATE391915T1/de not_active IP Right Cessation
- 2001-08-07 JP JP2002517534A patent/JP4868692B2/ja not_active Expired - Fee Related
- 2001-08-07 ES ES01963064T patent/ES2304393T3/es not_active Expired - Lifetime
- 2001-08-07 DK DK01963064T patent/DK1314040T3/da active
- 2001-08-07 WO PCT/FR2001/002561 patent/WO2002012901A2/fr not_active Ceased
- 2001-08-07 US US10/344,223 patent/US20050100972A1/en not_active Abandoned
-
2011
- 2011-08-03 US US13/197,242 patent/US8852878B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002012901A2 (fr) | 2002-02-14 |
| EP1314040A2 (de) | 2003-05-28 |
| DE60133563D1 (de) | 2008-05-21 |
| FR2812945B1 (fr) | 2002-10-04 |
| JP4868692B2 (ja) | 2012-02-01 |
| AU8411201A (en) | 2002-02-18 |
| WO2002012901A3 (fr) | 2002-09-06 |
| CA2418655A1 (fr) | 2002-02-14 |
| CA2418655C (fr) | 2011-12-13 |
| DK1314040T3 (da) | 2008-08-04 |
| DE60133563T2 (de) | 2009-04-30 |
| FR2812945A1 (fr) | 2002-02-15 |
| AU2001284112B2 (en) | 2007-03-22 |
| US20120009604A1 (en) | 2012-01-12 |
| ES2304393T3 (es) | 2008-10-16 |
| JP2004537961A (ja) | 2004-12-24 |
| US20050100972A1 (en) | 2005-05-12 |
| EP1314040B1 (de) | 2008-04-09 |
| US8852878B2 (en) | 2014-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marmol | Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium | |
| AU6132701A (en) | Novel multicyclic compounds and the use thereof | |
| WO2006002262A3 (en) | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder | |
| UA95244C2 (ru) | Соединения и способ модулирования активности киназ, и показания для их применения | |
| GB2364059A (en) | Beta-Secretase enzyme compositions and methods | |
| NO20070951L (no) | Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse. | |
| ECSP088262A (es) | Proteínas de fusión de albúmina | |
| AU2005253776A8 (en) | Screening methods using c-Abl, Fyn and Syk in combination with tau protein | |
| ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| ZA99133B (en) | Transgenic rabbit that expresses a functional human lipoprotein (A). | |
| MX2009006685A (es) | Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos. | |
| DE60131550D1 (en) | Gsk3-polypeptide | |
| DK1007638T3 (da) | KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf | |
| DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
| ATE391915T1 (de) | Verwendung des proteins grf-1 zur auswahl von molekülen | |
| WO2006042137A3 (en) | Methods for identifying parkinson's disease therapeutics | |
| WO2007035722A3 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | |
| WO2004089982A3 (en) | April variants and methods thereof | |
| WO2007067512A3 (en) | Method for identifying modulators of adprh useful for treating alzheimer's disease | |
| ATE378052T1 (de) | Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
| ATE454147T1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten | |
| DK1670309T3 (da) | Transgenetiske dyr med større lidelser i forbindelse med Alzheimers sygdom | |
| WO2004096199A3 (en) | Regulation of guanine nucleotide exchange factor | |
| WO2004073731A8 (en) | 14-3-3 protein for prevention and treatment of fibroproliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |